Physician profile
John M Englehardt
NPI 1154320307
$5,703.58
in general payments reported to CMS, 2019-2025
32 companies · $735 in 2025
The $735 reported for 2025 was less than what a typical Clinical Cardiac Electrophysiology provider received nationally (typical 2025 total: $2,477).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $829 · 2020: $447 · 2021: $619 · 2022: $1,001 · 2023: $903 · 2024: $1,169 · 2025: $735.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,807.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,807.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $627.78 | 2019-2024 | |
| Biotronik INC. | $614.60 | 2019-2023 | Acticor 7 Vr-T Dx |
| Irhythm Technologies, INC. | $571.52 | 2020-2024 | Zio Xt Patch, Zio Monitor |
| Boston Scientific Corporation | $551.74 | 2019-2025 | Watchman Flx, Farapulse |
| E.R. Squibb & Sons, L.L.C. | $457.35 | 2020-2025 | Camzyos, Eliquis |
| Medtronic, INC. | $437.04 | 2021-2025 | Aurora Ev-Icd Mri Surescan, Cobalt Dr Mri Surescan, Azure Xt Dr Mri Surescan |
| Abbott Laboratories | $390.70 | 2019-2025 | Jot Dx |
| Pfizer INC. | $273.04 | 2019-2025 | |
| Amgen INC. | $230.38 | 2019-2024 | Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $230.36 | 2019-2025 | Lifevest |
| Edwards Lifesciences Corporation | $217.02 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $203.97 | 2019-2024 | Jardiance |
| Janssen Pharmaceuticals, INC | $179.07 | 2019-2021 | |
| Kestra Medical Technology Services, INC. | $79.32 | 2023-2025 | Assure Wcd |
| Merck Sharp & Dohme LLC | $72.87 | 2022-2025 | Verquvo |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $65.85 | 2020-2023 | |
| Celgene Corporation | $62.61 | 2022-2024 | Camzyos |
| Kiniksa Pharmaceuticals International, Plc | $54.25 | 2024 | Arcalyst |
| Davol INC. | $54.05 | 2021 | |
| Impulse Dynamics (USA) INC. | $45.06 | 2022-2023 | Optimizer |
| Philips North America LLC | $39.71 | 2022-2023 | |
| Elutia, INC. | $38.49 | 2021 | |
| Esperion Therapeutics, INC. | $36.09 | 2021 | |
| Heartflow, INC. | $35.80 | 2023-2024 | Ffrct |
| Astrazeneca Pharmaceuticals LP | $29.01 | 2019-2020 | |
| Cvrx, INC. | $18.83 | 2023 | Barostim Neo System |
| Atricure, INC. | $17.39 | 2022 | |
| Alnylam Pharmaceuticals INC. | $16.63 | 2020 | |
| Novo Nordisk INC | $14.86 | 2025 | Wegovy |
| Zimvie INC. | $13.61 | 2022 | |
| Genzyme Corporation | $13.47 | 2022 | |
| Medtronic Vascular, INC. | $11.11 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Englehardt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.